Pfizer New Zealand has signed an agreement with the New Zealand government to supply 60,000 treatment courses of its early stage COVID-19 oral antiviral product ritonavir.
If the drug gets regulatory approval from Medsafe it would be the first oral antiviral of its kind. A rolling regulatory submission is under way for provisional approval.
Under the terms of the agreement, the New Zealand government will acquire an initial quantity of 60,000 treatment courses over the course of 2022.
Pfizer said its pricing was based on the principles of advance commitment, volume, equity and affordability.
“We are honoured to work with the New Zealand government toward achieving our shared goal of addressing this public health crisis,” Pfizer New Zealand managing director Anne Harris said.
“If approved , oral protease inhibitor antiviral therapies may help to reduce the severity or onset of illness in adults who contract, or have been exposed to, COVID-19.
“An oral treatment option may thus be an important potential tool to help address the ongoing global impact of the COVID-19 pandemic.”